Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer
Blood tests can identify pre-treatment cancer mutations that predict how breast cancer will respond to hormone therapy, guiding smarter treatment sequencing.
Large real-world ctDNA database analysis demonstrates that a CDK4/6i resistance mutation signature identified pre-treatment predicts significantly worse survival outcomes in HR+ metastatic breast cancer, with ESR1 and RB1 alterations further enriched after CDK4/6i exposure. Findings support ctDNA-based resistance profiling before CDK4/6i initiation to guide personalized treatment sequencing.
What the study was
- Study design
- Real-world retrospective clinical-genomic database analysis
- Population
- HR+/HER2- metastatic breast cancer patients, CDK4/6i + ET treated
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- NPJ Breast Cancer
Why it surfaced
Large real-world Guardant database; ctDNA resistance panel directly implementable pre-CDK4/6i for HR+ mBC treatment sequencing.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.